Genomics and Proteomics Markets in Australia

SUMMARY

Increasing Research Drives Genomics and Proteomics Market in Australia

Extensive research in genomics and proteomics is promising cures for previously untreatable diseases. With the Government assisting by providing additional tax concessions, the spending on research and development (R&D) is likely to increase by 66.0 percent in 2005. As a result, more than 300 biotechnology companies focusing on genomics and proteomics applications have set up operations in Australia to take advantage of this favorable environment. Drug discovery companies are also likely to have ample opportunities to slightly modify the lead compound in order to screen and exclude patients of a certain genotype who are more prone to developing certain side effects from clinical trials.

This Frost & Sullivan research service provides an overview of and an outlook for the Australian genomics and proteomics market. It segments the market into structural and functional genomics and structural and functional proteomics. It provides detailed revenue forecasts and market share analyses and is essential for both large and small market participants seeking to position themselves to earn maximum return on investments.

Research Companies Must Team-up with Venture Capitalists for Funds

Compared to Western countries, most of the Australian biotech companies are start-up undertakings that are in need of capital to support their research. However, venture capitalists (VCs) are hesitant to provide funds since these companies have few products in the final stages of drug discovery and have to wait for around ten years for their products to complete clinical trials before releasing them into the market.

"The long gestation period and the low market awareness on the potential of biotech products have led to insufficient funding of the biotech ventures in Australia as investors perceive them as being too risky," points out the analyst of the research service. "The Australian government and the top research companies should help VCs understand the commercial viability of their projects and the time required to market them." To do this, they need to work closer with the VCs and convince them of the effectiveness of their approaches in procuring positive results in the clinical trials.

Enterprises Must Supply Researchers with Superior Products at Lesser Costs

"Researchers need to strike the right balance between choosing high-end products for their research and maintaining lower costs," emphasizes the analyst. "New products such as those in structural proteomics can be expensive, and at times, complex and enterprises should convince researchers about their long-term benefits to drive their sales."

To encourage greater involvement in research from universities, biotech companies must educate the faculty on intellectual property (IP) issues, patent filing, and tracking of license agreements with third parties, and monitoring competitors' technologies. These universities need to allot more resources for developing enhanced commercialization processes and build managerial expertise in commercialization, deal structuring, and business development.

TABLE OF CONTENTS

• 1. Research Objectives and Approach
  • 1. Research Objectives
    • 1. Objectives
  • 2. Research Approach
    • 1. Approach Used for Doing the Study
• 2. Assumptions and Definitions
  • 1. Assumptions
    • 1. List of Assumptions
    • 2. Currency Conversion
  • 2. Definitions
    • 1. List of Definitions
• 3. Executive Summary
  • 1. Summary of Findings
    • 1. Summary
• 4. Total Market Analysis
  • 1. R&D Trends
    • 1. R&D Expenditure
  • 2. Total Genomics and Proteomics Markets
    • 1. Total Market
  • 3. Life Sciences Funding and Deals
    • 1. Funding and Deals in the Australian Genomics and Proteomics Sectors
  • 4. Market Drivers and Restraints
    • 1. Market Drivers
    • 2. Market Restraints
  • 5. Industry Challenges
    • 1. Industry Challenges
  • 6. Opportunity Areas
    • 1. The Major Opportunity Areas
  • 7. Market Maturation Process
    • 1. Life Cycle Analysis of the Genomics and Proteomics Market
  • 8. Strategic Anticipation
    • 1. I Think it Might Happen
  • 9. Competition Framework
    • 1. Porter Analysis
  • 10. Initiatives
    • 1. Government Initiatives
• 5. Analysis of Genomics Market in Australia
  • 1. Segmentation
    • 1. Market Segmentation
  • 2. Market Engineering Measurements
    • 1. Description
  • 3. Market Challenges
    • 1. Market Challenges Affecting the Genomics Market
  • 4. Market Drivers
    • 1. Market Drivers
  • 5. Total Market Size
    • 1. Revenue Forecasts
  • 6. Total Market Sub-segmentation Size
    • 1. Revenue Growth for Structural and Functional Genomics Market
  • 7. Market Trends
    • 1. Key Market Trends
  • 8. Executive Quote-1
    • 1. The Quote
  • 9. Technology Trends
    • 1. Key Technology Trends
  • 10. Market Opportunities
    • 1. Opportunities in the Genomics Market
  • 11. Executive Quote-2
    • 1. The Quote
• 6. Analysis of Proteomics Market in Australia
  • 1. Segmentation
    • 1. Market Segmentation
  • 2. Market Engineering Measurements
    • 1. Description
  • 3. Market Challenges
    • 1. Market Challenges Affecting the Proteomics Market
  • 4. Market Drivers
    • 1. Market Drivers
  • 5. Total Market Size
    • 1. Revenue Forecasts
  • 6. Total Market Sub-Segementation Size
    • 1. Revenue Forecasts for Structural and Functional Proteomics Market
  • 7. Molecular Structure Determination
    • 1. Revenue Forecast of the Molecular Structure Determination Market
  • 8. Market Trends
    • 1. Key Market Trends
  • 9. Executive Quote-1
    • 1. The Quote
  • 10. Technology Trends
    • 1. Key Technology Trends
  • 11. Market Opportunities
    • 1. Opportunities in the Proteomics Market
  • 12. Executive Quote-2
    • 1. The Quote
• 7. Competitor Analysis
  • 1. Main Participants
    • 1. Main Participants in Genomics and Proteomics Market
  • 2. Tiers of Competition
    • 1. Tiers of Competition
• 8. Major Events
  • 1. The Major Events
    • 1. Major Events in the Genomics and Proteomics Landscape in Australia
• 9. Strategic Recommendations
  • 1. Recommendations
    • 1. Collaborative Efforts for more VC Funding
    • 2. Importance of Partnerships and Tie-ups
    • 3. Timelines for Products to Move from Basic Research to Clinical Research
    • 4. Forming R&D Policies
    • 5. Focus on Commercialization of Projects
• 10. Frost and Sullivan Awards
  • 1. Technology Innovation Award
    • 1. Award-1
  • 2. Business Development Strategy Leadership Award
    • 1. Award-2
  • 3. Genomics Company of the Year Award
    • 1. Award-3
  • 4. Entrepreneurial Company Award
    • 1. Award-4
  • 5. Product Innovation Leadership Award
    • 1. Award-5
  • 6. Technology Leadership Award
    • 1. Award-6

List Of Figures

Chapter 1

• Research and Development Trends, 1999-2006
• Market drivers, restraints and challenges, CEO Speak
• Market Maturation Process
• Opportunity Level portrayed in Competitive Framework

Chapter 2

• Market Segmentation
• Market Engineering Measurements
• Industry Challenges
• Market drivers Ranked in the order of Impact (Australia), 2004-2007
• Market Size and Growth for Structural and Functional Genomics, 2002-2007
• Market Size and Growth of Structural and Functional Genomics sub-segments, 2002-2007

Chapter 3

• Market Segmentation
• Market Engineering Measurements
• Industry Challenges
• Market drivers Ranked in the order of Impact (Australia), 2004-2007
• Market Size and Growth for Structural and Functional Proteomics, 2002-2007
• Market Size and Growth of Structural and Functional Proteomics sub-segments, 2002-2007
• Tiers of Competition